Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Randomized, Double-blind Study to Evaluate and Compare the Efficacy and Safety of 8-week Treatment With AZM and AML Combined and Alone in Mild-to-moderate Essential Hypertensive Subjects

NCT05385770 is registered in ClinicalTrials.gov with Celltrion as lead sponsor.

NCT NCT05385770
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05385770 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Randomized, Double-blind Study to Evaluate and Compare the Efficacy and Safety of 8-week Treatment With AZM and AML Combined and Alone in Mild-to-moderate Essential Hypertensive Subjects
Lead sponsor
Celltrion
Phase
Phase 3
Overall status
Completed
Start date
July 8, 2022
Completion date
July 19, 2024
Enrollment
890 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

essential hypertension